Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria | Haematologica

Raphael Itzykson; Claude Gardin; Cécile Pautas; Xavier Thomas; Pascal Turlure; Emmanuel Raffoux

首页> 外文期刊>Haematologica >Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria | Haematologica

【24h】

Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria | Haematologica

机译：缓解后治疗对65-70岁从头急性髓样白血病患者的影响：两项同时纳入年龄重叠标准的随机ALFA试验的比较|血液学

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background There is no standard post-remission therapy in older patients with acute myeloid leukemia.

机译：背景技术对于老年急性髓性白血病，尚无标准的缓解后治疗方法。

著录项

来源
《Haematologica 》 |2011年第6期| 共8页
作者
Raphael Itzykson; Claude Gardin; Cécile Pautas; Xavier Thomas; Pascal Turlure; Emmanuel Raffoux;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy [J] . DeAngelo Daniel J., Sekeres Mikkael A., Ottmann Oliver G., Clinical lymphoma, myeloma & leukemia . 2015 ,第Suppla1期

机译：III阶段随机试验的Volasertib与低剂量的溶剂（LDAC）与安慰剂加上LDAC，= 65岁的患者，= 65岁，急性未经治疗，急性髓性白血病（AML）不合适，不合适
2. Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age = 60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial [J] . Foran James M., Sun Zhuoxin, Paietta Elisabeth, Blood: The Journal of the American Society of Hematology . 2018 ,第NovaelaTreatmentAppr期

机译：在完全缓解时，通常检测到最小的残留疾病（MRD）在急性髓性白血病（AML）患者年龄＆ = 60年来基于缓解后处理策略显着影响结果：对ECOG-acrin（EA）E2906的前瞻性分析第三阶段试验
3. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years | Haematologica [J] . M Schaich, T Illmer, W Aulitzky, Haematologica . 2002 ,第8期

机译：高剂量米托蒽醌，依托泊苷，间氨苯ac胺和高剂量ara-C的强化双重诱导治疗，用于61-65岁的老年急性髓细胞白血病患者|血液学
4. Computationally derived cytological image markers for predicting risk of relapse in acute myeloid leukemia patients following bone marrow transplantation [C] . Sara ArabYarmohammadi, Zelin Zhang, Patrick Leo, Conference on Medical Imaging: Digital Pathology . 2020

机译：计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
5. Development of a Selective and Stable Reactive Oxygen Species-activated Anti-Acute Myeloid Leukemia Agent and Localizing DNA Aptamer [D] . Earnest, Kaylin Grace. 2018

机译：开发一种选择性和稳定的活性氧物质 - 活化的抗急性髓性白血病药剂和定位DNA适体
6. Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria [O] . Raphael Itzykson, Claude Gardin, Cécile Pautas, 2011

机译：缓解后治疗对65-70岁的从头急性髓样白血病患者的影响：两项同时纳入年龄重叠标准的随机ALFA试验的比较
7. Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria [O] . Itzykson, Raphael, Gardin, Claude, Pautas, Cécile, 2011

机译：缓解后治疗对65-70岁从头急性髓样白血病患者的影响：两项同时纳入年龄重叠标准的随机ALFA试验的比较

Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria | Haematologica

摘要

著录项

相似文献

相关主题

期刊订阅